Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 10, 2014, Pages 1593-1598

  Klettner, Alexa ^a   Recber, Muhammed ^a   Roider, Johann ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Aflibercept; Bevacizumab; Efficacy; Ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHOROID; COMPARATIVE STUDY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; ORGAN CULTURE TECHNIQUE; PIGMENT EPITHELIUM; SWINE; TIME; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; ENZYME-LINKED IMMUNOSORBENT ASSAY; ORGAN CULTURE TECHNIQUES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL PIGMENT EPITHELIUM; SWINE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925884610     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2719-y     Document Type: Article

References (34)

1. Velez-Montoya R, Oliver SCN, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H (2013) Current knowledge and trends in age-related macular degeneration. Today’s and futures treatments. Retina 33:1487–1502
2. Mitchell P, Korobelnik JF, Lanzetta P et al (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2–13
3. Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548
4. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S (2010) Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye 24:816–824
5. Harding SP (2010) Neovascular age-related macular degeneration: decision-making and optimal management. Eye 24:497–505
6. Hörster R, Ristau T, Sadda SR, Liakopoulos S (2011) Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 249:645–652
7. Klettner A (2013) Physiological functions of VEGF in the retina and its possible implications on prolonged VEGF therapy. In: Parker ML (ed) Vascular Endothelial Growth Factor (VEGF), Biology, Regulation and Clinical Significance. Nova Biomedical, New York, pp 117–136
8. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, The Tübingen Bevacizumab Study Group, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995–1002
9. Gerber HP, McMurtrey A, Kowalski J et al (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’kinase/Akt signal transduction pathway. J Biol Chem 273:30336–30343
10. Byeon S, Lee S, Choi S et al (2010) Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Invest Ophthalmol Vis Sci 51:1190–1197
11. Kilic Ü, Kilic E, Järve A et al (2006) Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating Erk1/2 and Akt pathways. J Neurosci 26:12439–12446
12. Ueno S, Pease ME, Wersinger DM et al (2008) Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 217:13–22
13. Miki A, Miki K, Ueno S et al (2010) Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J Cell Physiol 224:262–272
14. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M (2010) Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122:4213–4217
15. Ford KM, Saint-Geniez M, Walshe T, Zahr A, D’Amore PA (2011) Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis 52:9478–9487
16. Saint-Geniez M, Maharaj ASR, Walshe TE et al (2008) Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PloS One 3:1–13
17. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B; MARINA and ANCHOR Study Groups (2011) Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 118:523–530
18. Mariani A, Deli A, Ambresin A, Mantel I (2011) Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 249:1635–1642
19. Klettner A, Roider J (2008) Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49:4523–4527
20. Klettner A, Westhues D, Lassen J, Bartsch S, Roider J (2013) Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: p38, nuclear factor kappaB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway. Mol Vis 19:281–291
21. Minuth WW, Kloth S, Aigner J, Sittinger M, Röckl W (1996) Approach to an organo-typical environment for cultured cells and tissues. Biotechniques 20:498–501
22. Miura Y, Klettner A, Noelle B, Hasselbach H, Roider J (2010) Change of morphological and functional characteristics of retinal pigment epithelium cells during cultivation of retinal pigment epithelium–choroid perfusion tissue culture. Ophthalmic Res 43:122–133
23. Lassota N (2008) Clinical and histological aspects of CNV formation: studies in an animal model. Acta Ophthalmol 86(2):1–24
24. Sanchez I, Martin R, Ussa F, Fernandez-Bueno I (2011) The parameters of the porcine eyeball. Graefes Arch Clin Exp Ophthalmol 249:475–482
25. Middleton S (2010) Porcine ophthalmology. Vet Clin Food Anim 26:557–572
26. Butler J, Sun J, Wertz N, Sinkora M (2006) Antibody repertoire development in swine. Dev Comp Immunol 30:199–211
27. Yang P, Chen L, Zwart R, Kijlstra A (2002) Immune cells in the porcine retina: distribution, characterization and morphological features. Invest Ophthalmol Vis Sci 43:1488–1492
28. Klettner A, Koinzer S, Meyer T, Roider J (2013) Toll-like receptor 3 activation in retinal epithelium cells—mitogen-activated protein kinase pathways of cell death and vascular endothelial growth factor secretion. Acta Ophthalmol 91:e211–218
29. Yu L, Liang XH, Ferrara N (2011) Comparing protein VEGF-inhibitors: invitro biological studies. Biochem Biophys Res Commun 408:276–281
30. Papadopoulos N, Martin J, Ruan Q etal (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab, bevacizumab. Angiogenesis 15:171–185
31. Shiose S, Hata Y, Noda Y, Sassa Y, Takeda A, Yoshikawa H, Fujisawa K, Kubota T, Ishibashi T (2004) Fibrinogen stimulates invitro angiogenesis by choroidal endothelial cells via autocrine VEGF. Graefes Arch Clin Exp Ophthalmol 242:777–83
32. Jin J, Yuan F, Shen MQ, Feng YF, He QL (2013) Vascular endothelial growth factor regulates primate choroid-retinal endothelial cell proliferation and tube formation through PI3K/Akt and MEK/ERK dependent signaling. Mol Cell Biochem 381:267–72
33. Ottino P, Finley J, Rojo E, Ottlecz A, Lambrou GN, Bazan HE, Bazan NG (2004) Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: involvement of cytosolic phospholipase A2 activity. Mol Vis 10:341–50
34. Klettner A, Doths J, Roider J (2012) Nicotine reduces VEGF-secretion and phagocytotic activity in porcine RPE. Graefes Arch Clin Exp Ophthalmol 250:33–38